The generic name of Rebaian is iloyumab injection, which can lower lipids. Eloxacinumab Injection is a PCSK9 inhibitor, a new class of new clinical lipid-lowering drugs; it is commonly used in the treatment of familial hypercholesterolemia, atherosclerotic cardiovascular disease in adults, and has the effect of lowering low-density lipoproteins, and decreasing the risk of myocardial infarction, stroke, and coronary artery blood flow reconstruction. ADVERSE REACTIONS: Adverse reactions such as upper respiratory tract infections, gastroenteritis, nasopharyngitis, erythema and bruising at the injection site, and rash may occur with this drug. Precautions: If signs or symptoms of a severe allergic reaction occur, treatment with Rebifen must be discontinued, treated according to the standard regimen, and monitored until signs and symptoms resolve. CONTRAINDICATIONS: It is contraindicated in patients with a history of severe hypersensitivity to the components of the product. The use of Eloxacinumab Injection should be under the supervision of a physician and immediate medical attention should be sought in case of discomfort.